Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Safety and immunogenicity of a replication-defective adenovirus type 5 HIV vaccine in Ad5-seronegative persons: a randomized clinical trial (HVTN 054).

Peiperl L, Morgan C, Moodie Z, Li H, Russell N, Graham BS, Tomaras GD, De Rosa SC, McElrath MJ; NIAID HIV Vaccine Trials Network.

PLoS One. 2010 Oct 27;5(10):e13579. doi: 10.1371/journal.pone.0013579.

2.

Safety and Immunogenicity of the MRKAd5 gag HIV Type 1 Vaccine in a Worldwide Phase 1 Study of Healthy Adults.

Nicholson O, Dicandilo F, Kublin J, Sun X, Quirk E, Miller M, Gray G, Pape J, Robertson MN, Mehrotra DV, Self S, Turner K, Sanchez J, Pitisuttithum P, Duerr A, Dubey S, Kierstead L, Casimiro D, Hammer SM; for the Merck V520-018/HIV Vaccine Trials Network 050 Study Team.

AIDS Res Hum Retroviruses. 2010 Nov 23. [Epub ahead of print]

3.

Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells.

Payne RP, Kløverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, Sims S, Hickling S, Riddell L, Chen F, Luzzi G, Edwards A, Phillips R, Prado JG, Goulder PJ.

J Virol. 2010 Oct;84(20):10543-57. doi: 10.1128/JVI.00793-10. Epub 2010 Aug 4.

4.

Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype.

Dinges WL, Richardt J, Friedrich D, Jalbert E, Liu Y, Stevens CE, Maenza J, Collier AC, Geraghty DE, Smith J, Moodie Z, Mullins JI, McElrath MJ, Horton H.

J Virol. 2010 May;84(9):4461-8. doi: 10.1128/JVI.02438-09. Epub 2010 Feb 10.

5.

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, Nason MC, Larkin BD, Enama ME, Ledgerwood JE, Bailer RT, Mascola JR, Nabel GJ, Graham BS; VRC 009 Study Team; VRC 010 Study Team.

PLoS One. 2010 Feb 2;5(2):e9015. doi: 10.1371/journal.pone.0009015.

6.

Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance.

Tenzer S, Wee E, Burgevin A, Stewart-Jones G, Friis L, Lamberth K, Chang CH, Harndahl M, Weimershaus M, Gerstoft J, Akkad N, Klenerman P, Fugger L, Jones EY, McMichael AJ, Buus S, Schild H, van Endert P, Iversen AK.

Nat Immunol. 2009 Jun;10(6):636-46. doi: 10.1038/ni.1728. Epub 2009 May 3.

PMID:
19412183
7.

Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge.

Wilson NA, Keele BF, Reed JS, Piaskowski SM, MacNair CE, Bett AJ, Liang X, Wang F, Thoryk E, Heidecker GJ, Citron MP, Huang L, Lin J, Vitelli S, Ahn CD, Kaizu M, Maness NJ, Reynolds MR, Friedrich TC, Loffredo JT, Rakasz EG, Erickson S, Allison DB, Piatak M Jr, Lifson JD, Shiver JW, Casimiro DR, Shaw GM, Hahn BH, Watkins DI.

J Virol. 2009 Jul;83(13):6508-21. doi: 10.1128/JVI.00272-09. Epub 2009 Apr 29.

8.

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.

Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, Legasse AW, Axthelm MK, Oswald K, Trubey CM, Piatak M Jr, Lifson JD, Nelson JA, Jarvis MA, Picker LJ.

Nat Med. 2009 Mar;15(3):293-9. doi: 10.1038/nm.1935. Epub 2009 Feb 15. Erratum in: Nat Med. 2009 Apr;15(4):462. Nat Med. 2011 Dec;17(12):1692.

9.

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN; Step Study Protocol Team.

Lancet. 2008 Nov 29;372(9653):1881-1893. doi: 10.1016/S0140-6736(08)61591-3. Epub 2008 Nov 13.

10.

Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance.

Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, Cheroutre H, von Herrath MG, Buchmeier MJ, Grey H, Sette A.

J Immunol. 2008 Aug 1;181(3):2124-33.

11.

Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide-MHC class I complexes.

Thirdborough SM, Roddick JS, Radcliffe JN, Howarth M, Stevenson FK, Elliott T.

Eur J Immunol. 2008 Feb;38(2):364-9. doi: 10.1002/eji.200737832.

12.

Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection.

Lichterfeld M, Yu XG, Mui SK, Williams KL, Trocha A, Brockman MA, Allgaier RL, Waring MT, Koibuchi T, Johnston MN, Cohen D, Allen TM, Rosenberg ES, Walker BD, Altfeld M.

J Virol. 2007 Apr;81(8):4199-214. Epub 2007 Feb 7.

13.

Preservation of T cell proliferation restricted by protective HLA alleles is critical for immune control of HIV-1 infection.

Horton H, Frank I, Baydo R, Jalbert E, Penn J, Wilson S, McNevin JP, McSweyn MD, Lee D, Huang Y, De Rosa SC, McElrath MJ.

J Immunol. 2006 Nov 15;177(10):7406-15.

14.

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation.

Li F, Malhotra U, Gilbert PB, Hawkins NR, Duerr AC, McElrath JM, Corey L, Self SG.

Vaccine. 2006 Nov 17;24(47-48):6893-904. Epub 2006 Jun 27.

PMID:
16890329
15.

Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines.

Kaslow RA, Rivers C, Tang J, Bender TJ, Goepfert PA, El Habib R, Weinhold K, Mulligan MJ; NIAID AIDS vaccine evaluation group.

J Virol. 2001 Sep;75(18):8681-9.

16.
17.

Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS.

Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, O'Brien SJ, Carrington M.

N Engl J Med. 2001 May 31;344(22):1668-75.

18.

Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection.

Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, Addo MM, He S, Mukherjee JS, Phillips MN, Bunce M, Kalams SA, Sekaly RP, Walker BD, Brander C.

J Exp Med. 2001 Jan 15;193(2):181-94.

19.

Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses.

Yewdell JW, Bennink JR.

Annu Rev Immunol. 1999;17:51-88. Review.

PMID:
10358753

Supplemental Content

Support Center